DK0402068T3 - Polypeptider og polypeptidanaloger med inhiberende virkning mod human elastase - Google Patents

Polypeptider og polypeptidanaloger med inhiberende virkning mod human elastase

Info

Publication number
DK0402068T3
DK0402068T3 DK90306037.4T DK90306037T DK0402068T3 DK 0402068 T3 DK0402068 T3 DK 0402068T3 DK 90306037 T DK90306037 T DK 90306037T DK 0402068 T3 DK0402068 T3 DK 0402068T3
Authority
DK
Denmark
Prior art keywords
pro
cys
polypeptides
lys
gly
Prior art date
Application number
DK90306037.4T
Other languages
Danish (da)
English (en)
Inventor
Enno Prof Christophers
Jens-Michael Dr Schroder
David Dr Pioli
Oliver Dr Wiedow
Michael Derek Dr Edge
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898913349A external-priority patent/GB8913349D0/en
Priority claimed from GB898913346A external-priority patent/GB8913346D0/en
Priority claimed from GB898921613A external-priority patent/GB8921613D0/en
Priority claimed from GB898924717A external-priority patent/GB8924717D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DK0402068T3 publication Critical patent/DK0402068T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK90306037.4T 1989-06-09 1990-06-04 Polypeptider og polypeptidanaloger med inhiberende virkning mod human elastase DK0402068T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898913349A GB8913349D0 (en) 1989-06-09 1989-06-09 Polypeptides
GB898913346A GB8913346D0 (en) 1989-06-09 1989-06-09 Polypeptide analogues
GB898921613A GB8921613D0 (en) 1989-09-25 1989-09-25 Polypeptides-1st update
GB898924717A GB8924717D0 (en) 1989-11-02 1989-11-02 Polypeptides

Publications (1)

Publication Number Publication Date
DK0402068T3 true DK0402068T3 (da) 1996-04-22

Family

ID=27450350

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90306037.4T DK0402068T3 (da) 1989-06-09 1990-06-04 Polypeptider og polypeptidanaloger med inhiberende virkning mod human elastase

Country Status (16)

Country Link
US (4) US5464822A (fr)
EP (1) EP0402068B1 (fr)
JP (1) JP2989853B2 (fr)
AT (1) ATE131493T1 (fr)
AU (1) AU636148B2 (fr)
CA (1) CA2018592C (fr)
DE (1) DE69024104T2 (fr)
DK (1) DK0402068T3 (fr)
ES (1) ES2080800T3 (fr)
FI (1) FI106471B (fr)
GR (1) GR3018401T3 (fr)
IE (1) IE70520B1 (fr)
IL (1) IL94602A (fr)
NO (1) NO177716C (fr)
NZ (1) NZ233974A (fr)
PT (1) PT94326B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
ES2129401T3 (es) * 1990-05-24 1999-06-16 Zeneca Ltd Uso de un compuesto terapeutico para el tratamiento de bronquitis.
DK0458536T3 (da) * 1990-05-24 1998-10-19 Zeneca Ltd Terapeutisk middel til behandling og forebyggelse af åndedrætsbesværsyndrom hos voksne
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US8606851B2 (en) 1995-06-06 2013-12-10 Wayport, Inc. Method and apparatus for geographic-based communications service
US5835061A (en) 1995-06-06 1998-11-10 Wayport, Inc. Method and apparatus for geographic-based communications service
EP0834556A1 (fr) * 1996-09-25 1998-04-08 Academisch Ziekenhuis Leiden Procédés de culture de cellules
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2001241913A1 (en) * 2000-03-01 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for wound treatment
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
EP2290098A1 (fr) 2002-01-28 2011-03-02 Ambion, Inc. Production des extraits biologiques bruts utilisant protease, convenant pour la synthèse de cDNA
WO2003090682A2 (fr) * 2002-04-25 2003-11-06 The Scripps Research Institute Traitement et prevention d'affections pulmonaires
FR2849375B1 (fr) * 2002-12-30 2006-10-20 Jean Noel Thorel Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit
CA2524626A1 (fr) * 2003-05-07 2004-11-18 Vib Vzw Utilisation d'un domaine polypeptidique pour moduler le potentiel tumorigene et metastatique de cellules cancereuses
US20090163409A1 (en) * 2005-05-16 2009-06-25 Ball T Blake Trappin-2 (elafin) inhibits HIV
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
EP2367954B1 (fr) * 2008-12-19 2015-02-18 Life Technologies Corporation Inhibiteurs de proteinase k, methodes et compositions d'iceux
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
EP4452303A4 (fr) * 2021-12-20 2025-11-12 Tiakis Biotech Ag Utilisation d'élafine dans le traitement de la covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
WO1990009737A1 (fr) * 1989-02-23 1990-09-07 The Center For Blood Research Inhibiteur de l'elastase humaine
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff

Also Published As

Publication number Publication date
IL94602A (en) 1996-06-18
US6893843B2 (en) 2005-05-17
AU636148B2 (en) 1993-04-22
EP0402068A1 (fr) 1990-12-12
PT94326B (pt) 1997-01-31
US5464822A (en) 1995-11-07
CA2018592A1 (fr) 1990-12-09
IE70520B1 (en) 1996-12-11
NO177716B (no) 1995-07-31
FI902880A0 (fi) 1990-06-08
DE69024104D1 (de) 1996-01-25
NO177716C (no) 1995-11-08
JP2989853B2 (ja) 1999-12-13
EP0402068B1 (fr) 1995-12-13
NZ233974A (en) 1993-05-26
FI106471B (fi) 2001-02-15
US20020187535A1 (en) 2002-12-12
ATE131493T1 (de) 1995-12-15
ES2080800T3 (es) 1996-02-16
AU5680890A (en) 1990-12-13
US6245739B1 (en) 2001-06-12
GR3018401T3 (en) 1996-03-31
DE69024104T2 (de) 1996-06-13
IL94602A0 (en) 1991-04-15
IE902006L (en) 1990-12-09
NO902444D0 (no) 1990-06-01
CA2018592C (fr) 2002-08-27
NO902444L (no) 1990-12-10
US20060068480A1 (en) 2006-03-30
PT94326A (pt) 1991-02-08
JPH03148299A (ja) 1991-06-25

Similar Documents

Publication Publication Date Title
DK0402068T3 (da) Polypeptider og polypeptidanaloger med inhiberende virkning mod human elastase
NO852673L (no) Tumor-nekrosefaktor.
DK0592566T3 (da) IL-6-muteiner med reduceret cysteinantal
DE3770661D1 (de) 1,2,3,4-tetrahydro-6-substituierte-4-aryl(oder heterozyklo)3-((substituierte amino)carbonyl)-2-thioxo(oder oxo)-5-pyrimidinkarbonsaeuren und -ester.
DE68917837D1 (de) Peptid-Verbindungen.
ES2177625T3 (es) Citoquina cc-1 humana circulante.
DK0378432T3 (da) Peptider, deres anvendelse til inhibering af modningen af T-lymfocytter og aktiviteten af makrofager samt fremgangsmåder til deres fremstilling
ES2080486T3 (es) Sg(beta)-1,4-galactanasa y una secuencia de adn.
ATA264487A (de) Homogene, rekombinante immun-interferonfragmente
DE69635630D1 (de) Verwendung eines Leukämie-hemmenden Faktor Antagonisten
CA2078000A1 (fr) Peptides stimulateurs de neutrophile
CA2118498A1 (fr) Nouvelle cytokine antineoplasique
ATE94168T1 (de) Peptide.
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
IT8821282A0 (it) Clonaggio del gene che codifica l'enzima isoamilasi e suo impiego per la produzione di detto enzima o suoi analoghi.
IT8821123A0 (it) Clonaggio del gene che codifica l'enzima isoamilasi e suo impiego per la produzione di detto enzima o suoi analoghi.
Gharavi Molecular cloning of the human lipoxygenase gene
CA2090121A1 (fr) Utilisations du facteur -1 de stimulation de colonies
IT209365Z2 (it) Struttura di schema particolare per giochi enigmistici del tipo parole crociate.